Elsevier

Human Pathology

Volume 25, Issue 12, December 1994, Pages 1269-1275
Human Pathology

Original contribution
Optimal primer selection for clonality assessment by polymerase chain reaction analysis: I. Low grade B-cell lymphoproliferative disorders of nonfollicular center cell type

https://doi.org/10.1016/0046-8177(94)90084-1Get rights and content

Abstract

Recent polymerase chain reaction (PCR)-based studies focused on the detection of immunoglobulin heavy chain gene (IgH) rearrangements have suggested that clonal populations may be amplified more easily from certain categories of B-cell neoplasia than others and that primer makeup can be a critical factor in successful amplification. However, these particular reports contained relatively few low grade B-cell lymphoproliferative disorders of nonfollicular center cell type (LG-BLPD) and used only a limited panel of available primer sets for PCR amplification of monoclonal B-cell populations. To address this issue more extensively we evaluated 156 samples of LG-BLPD by the PCR to determine optimal primer selection in this setting. All cases were classified according to standard morphological and immunophenotypic criteria, with monoclonality documented by Ig light chain restriction analysis. The LG-BLPD included 33 cases of chronic lymphocytic leukemia (CLL), 57 cases of small lymphocytic lymphoma (SLL), 10 cases of atypical CLL, 32 cases of mantle cell lymphoma (MCL), 17 plasma cell neoplasms (PCNs), and seven cases of hairy cell leukemia (HCL). All primer sets included a 3′ IgH joining region consensus primer, whereas the 5′ IgH variable region (VH) primer was different in each set. The first-line panel included the following: Set 1, VH-framework III consensus primer, and Set 2, seven separate VH-framework I family-specific primers. A reserve panel of alternate VH consensus primers directed at framework II or III regions was used only when Set 1 showed no evidence of B-cell monoclonality. Overall, monoclonal B-cell populations were amplified in 153 of 156 (98%) neoplasms by the PCR; two PCNs and one plasmacytoid SLL were negative with all primer pairs. Higher amplification efficiency was obtained with Set 1 primers than Set 2 primers in the entire series (96% ν 84%) as well as within each subtype of LG-BLPD. In each diagnostic category monoclonal B-cell populations were detected by Set 1 in 96% or more of neoplasms, the only exception being plasma cell neoplasms where the monoclonality detection rate was 76% (ie, 13 of 17 cases). With the additional use of Set 2 and the reserve panel primer sets, 15 of 17 (88%) PCNs were shown to contain PCR-detectable monoclonal B-cell populations. Our data suggest that the vast majority of CLLs, SLLs, MCL, and HCL samples can be successfully genotyped by the PCR with a single primer set (Set 1). In contrast, plasma cell tumors and rare SLL samples appear to require more extensive analysis (ie, additional primer sets) to adequately assess B-cell clonality.

References (42)

  • KP McCarthy et al.

    Rapid method for distinguishing clonal from polyclonal B cell populations in surgical biopsy specimens

    J Clin Pathol

    (1990)
  • GH Segal et al.

    Identification of monoclonal B-cell populations by rapid cycle polymerase chain reaction. A practical screening method for the detection of immunoglobulin gene rearrangements

    Am J Pathol

    (1992)
  • M Deane et al.

    Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B lineage leukemias

    Eur J Immunol

    (1990)
  • M Deane et al.

    An improved method for detection of B-lymphoid clonality by polymerase chain reaction

    Leukemia

    (1991)
  • J Ben Ezra

    Variable rate of detection of immunoglobulin heavy chain V-D-J rearrangement by PCR: A systematic study of 41 B-cell non-Hodgkin's lymphomas and leukemias

    Leuk Lymphoma

    (1992)
  • TC Diss et al.

    Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type

    J Pathol

    (1993)
  • N Corbally et al.

    The detection of specific gene rearrangements in non-Hodgkin's lymphoma using the polymerase chain reaction

    Br J Cancer

    (1992)
  • NM Almasri et al.

    Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia

    Am J Hematol

    (1992)
  • DD Weisenburger et al.

    Non-Hodgkin's lymphomas of mantle zone origin

    Pathol Annu

    (1991)
  • PM Banks et al.

    Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data

    Am J Surg Pathol

    (1992)
  • ES Jaffe et al.

    Histopathologic subtypes of indolent lymphomas: Caricatures of the mature B-cell system

    Semin Oncol

    (1993)
  • Cited by (147)

    • Polymerase Chain Reaction in the Diagnosis of Uveitis

      2018, Advances in Ophthalmology and Optometry
    • Lymph Nodes

      2012, Orell & Sterrett's Fine Needle Aspiration Cytology
    • Lymph nodes

      2011, Orell and Sterrett's Fine Needle Aspiration Cytology
    • Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype

      2009, Human Pathology
      Citation Excerpt :

      In addition, 3 of the 6 identified EBV-positive specimens underwent double-labeling immunohistochemical staining for EBER and either CD3 or CD20. Polymerase chain reaction (PCR) was performed with DNA extracted from formalin-fixed paraffin-embedded tissue from 3 of the 6 identified EBV-positive specimens for immunoglobulin heavy chain gene (IGH) rearrangement using a fluorescently labeled consensus primer specific for framework III of the IGH variable regions and a primer specific for the IGH joining region as previously described (Invitrogen, Carlsbad, CA) [14]. PCR was also performed on these 3 specimens for T-cell receptor γ gene rearrangement using consensus primers specific for the T-cell receptor gamma gene variable and joining regions (Invitrogen) [15].

    View all citing articles on Scopus
    1

    Dr Segal is a recipient of an American Cancer Society Clinical Oncology Career Development Award.

    View full text